TRAJENTA, known generically as linagliptin, is an oral diabetes medication that belongs to a class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors. It is primarily used in the management of type 2 diabetes, a condition characterized by high blood sugar levels due to the body's inability to produce enough insulin or to use insulin effectively. TRAJENTA works by increasing the levels of incretin hormones in the body, which in turn stimulates the release of insulin in response to high blood glucose levels and decreases the amount of sugar made by the liver. This helps to control blood sugar levels and prevents the long-term complications of diabetes. TRAJENTA is often prescribed in combination with diet and exercise, and it may be used alone or with other diabetes medications.